RxDoctor Payments Data

Allison Crowell, MD

Neurology · Lancaster, PANPI 1114312568

Payments from drug & device makers

$17,778in general payments, 2019–2025

Across 144 payments — averaging $123.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argenx US, Inc.$10K
  • AstraZeneca$4K
  • UCB, Inc.$515
  • EMD Serono, Inc.$349
  • AbbVie$343
  • E.r. Squibb & Sons, L.L.C.$292
  • plus $2K from 17 others

What the payments were for

  • Consulting fees$2,62515%
  • Speaking & faculty fees$9,40053%
  • Travel & lodging$3172%
  • Food & beverage$5,43631%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,778 in reported general payments places this provider in the 75th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$89,425
Medicare patients
292
Services billed
3,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UltomirisRavulizumab-Cwvz12$674,265
HizentraImmun Glob G(Igg)/Pro/Iga 0-5012$316,927
Emgality PenGalcanezumab-Gnlm68$52,547
Nurtec OdtRimegepant Sulfate31$34,421
Ajovy AutoinjectorFremanezumab-Vfrm33$28,857
Aimovig AutoinjectorErenumab-Aooe27$24,941
BotoxOnabotulinumtoxina18$22,656
EliquisApixaban20$17,186
Mycophenolate Mofetil56$11,630
Pyridostigmine Bromide ErPyridostigmine Bromide13$10,453
NayzilamMidazolam14$10,038
RytaryCarbidopa/Levodopa19$8,203
Pyridostigmine Bromide107$8,158
Levetiracetam133$5,506
Carbidopa-LevodopaCarbidopa/Levodopa139$4,953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaUltomiris$3,626$674,26512 claims
PfizerNurtec Odt, Eliquis$61$51,60751 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Rytary, Pyridostigmine Bromide$249$27,991182 claims
AbbVieBotox$343$22,65618 claims
UCB, Inc.Nayzilam$515$10,03814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →